BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 15888150)

  • 1. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.
    Geisse J; Caro I; Lindholm J; Golitz L; Stampone P; Owens M
    J Am Acad Dermatol; 2004 May; 50(5):722-33. PubMed ID: 15097956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks.
    Quirk C; Gebauer K; Owens M; Stampone P
    Australas J Dermatol; 2006 Nov; 47(4):258-65. PubMed ID: 17034468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
    Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
    Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
    Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
    J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
    Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
    Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study.
    Geisse JK; Rich P; Pandya A; Gross K; Andres K; Ginkel A; Owens M
    J Am Acad Dermatol; 2002 Sep; 47(3):390-8. PubMed ID: 12196749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
    Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
    J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study.
    Quirk C; Gebauer K; De'Ambrosis B; Slade HB; Meng TC
    Cutis; 2010 Jun; 85(6):318-24. PubMed ID: 20666194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imiquimod: in superficial basal cell carcinoma.
    Oldfield V; Keating GM; Perry CM
    Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice.
    Daudén E;
    J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1304-10. PubMed ID: 21348896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
    Neville JA; Williford PM; Jorizzo JL
    J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma.
    Ezughah FI; Dawe RS; Ibbotson SH; Fleming CJ
    J Dermatolog Treat; 2008; 19(2):111-7. PubMed ID: 17917935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
    Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
    Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
    Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
    Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream.
    Micali M; Nasca MR; Musumeci ML
    Int J Tissue React; 2005; 27(3):111-4. PubMed ID: 16372477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Swanson N; Smith CC; Kaur M; Goldenberg G
    J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma.
    Torres A; Niemeyer A; Berkes B; Marra D; Schanbacher C; González S; Owens M; Morgan B
    Dermatol Surg; 2004 Dec; 30(12 Pt 1):1462-9. PubMed ID: 15606733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.